From 'Make in India' to 'Made in India': the saroglitazar story

Affiliations

Editorial

Sivasubramanian Ramakrishnan. Indian Heart J. 2015 Jan-Feb.

. 2015 Jan-Feb;67(1):8-10.

doi: 10.1016/j.ihj.2015.02.014. Epub 2015 Mar 4.

¹ Additional Professor, Department of Cardiology, All India Institute of Medical Sciences, Delhi, India. Electronic address: ramaaiims@gmail.com.

No abstract available

Keywords: Indian pharmaceutical industry; Made in India; PPAR agonists; Saroglitazar.

Figures

Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
Shetty SR, Kumar S, Mathur RP, Sharma KH, Jaiswal AD. Shetty SR, et al. Indian Heart J. 2015 Jan-Feb;67(1):23-6. doi: 10.1016/j.ihj.2015.02.007. Epub 2015 Feb 26. Indian Heart J. 2015. PMID: 25820046 Free PMC article.

1. Pharmaceuticals; India in Business, Ministry of External Affairs, Govt. of India, Investment and Technology Promotion Division. Last updated on: Dec 4, 2014. http://indiainbusiness.nic.in/newdesign/index.php?param=industryservices.... Last assessed 03.02.15.
1. Pharmaceutical Industry in India; From Wikipedia. http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India. Last assessed 03.02.15.
1. Yusuf S., Pais P., Sigamani A. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium)versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes. 2012;5:463–471. - PubMed
1. Kuppuswamy V., Choo W.K., Gupta S. Polypill in cardiovascular disease: has it's time come? Indian Heart J. 2009;61:322–327. - PubMed
1. Marfurt J., Chalfein F., Prayoga P. Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax. Antimicrobial Agents Chemother. 2012;56:5258–5263. - PMC - PubMed